BIONXT SOLUTIONS INC. Market Cap ($23.70 Million)
Market Cap & Net Worth: BIONXT SOLUTIONS INC. (BXT)
BIONXT SOLUTIONS INC. market cap. BIONXT SOLUTIONS INC. (F:BXT) has a market capitalization of $23.70 Million (€20.27 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #24430 globally and #2112 in its home market, demonstrating a -7.74% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BIONXT SOLUTIONS INC.'s stock price €0.15 by its total outstanding shares 136055152 (136.06 Million). Also see cash flow conversion of BIONXT SOLUTIONS INC. for how efficiently the company converts equity into cash flow.
BIONXT SOLUTIONS INC. Market Cap History (2019–2026)
BIONXT SOLUTIONS INC. market cap history from 2019 to 2026. Data shows change from $112.14 Million to $23.70 Million (-22.03% CAGR). Check BXT stock price for real-time trading data and today's change.
BIONXT SOLUTIONS INC. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BIONXT SOLUTIONS INC.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore BIONXT SOLUTIONS INC. (BXT) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1556.14x
BIONXT SOLUTIONS INC.'s market cap is 1556.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $125.98 Million | $286.50K | -$20.64 Million | 439.72x | N/A |
| 2022 | $57.66 Million | $297.44K | -$12.38 Million | 193.85x | N/A |
| 2023 | $54.24 Million | $372.25K | -$7.72 Million | 145.71x | N/A |
| 2024 | $41.99 Million | $26.98K | -$5.31 Million | 1556.14x | N/A |
Competitor Companies of BXT by Market Capitalization
Companies near BIONXT SOLUTIONS INC. in the global market cap rankings as of November 4, 2026. Also see BXT total asset value for a full breakdown of the balance sheet.
Key companies related to BIONXT SOLUTIONS INC. by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #516 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #536 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #591 globally with a market cap of $45.45 Billion USD ( CN¥310.59 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #618 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #516 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #536 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.55 |
| #591 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.45 Billion | CN¥48.69 |
| #618 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of BIONXT SOLUTIONS INC. (2019–2026)
Market capitalization of BIONXT SOLUTIONS INC. from 2019 to today. Between 2019 and today, BIONXT SOLUTIONS INC.'s market cap moved from $112.14 Million to $ 23.70 Million, with a yearly change of -22.03%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €23.70 Million | -64.52% |
| 2025 | €66.81 Million | +59.09% |
| 2024 | €41.99 Million | -22.58% |
| 2023 | €54.24 Million | -5.93% |
| 2022 | €57.66 Million | -54.23% |
| 2021 | €125.98 Million | -36.39% |
| 2020 | €198.03 Million | +76.60% |
| 2019 | €112.14 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of BIONXT SOLUTIONS INC. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $23.70 Million USD |
| MoneyControl | $23.70 Million USD |
| MarketWatch | $23.70 Million USD |
| marketcap.company | $23.70 Million USD |
| Reuters | $23.70 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BIONXT SOLUTIONS INC.
BioNxt Solutions Inc. engages in research, development, manufacture, and sale of next generation drug formulations and delivery systems in Austria, Germany, and Switzerland. The company provides BNT23001for the treatment of multiple sclerosis and myasthenia gravis; BNT24002 for the treatment of lupus nephritis; BNT24003 for the treatment of rheumatoid arthritis; BNT24004 for longevity and anti-ag… Read more